The MIRA method for DNA methylation analysis

Division of Biology, Beckman Research Institute of the City of Hope, Duarte, CA, USA.
Methods in Molecular Biology (Impact Factor: 1.29). 02/2009; 507:65-75. DOI: 10.1007/978-1-59745-522-0_6
Source: PubMed


DNA methylation patterns are often altered in human cancer and aberrant methylation is considered a hallmark of malignant transformation. Several methods have been developed for the characterization of gene-specific and genome-wide DNA methylation patterns. In this chapter, we describe the methylated-CpG island recovery assay (MIRA), which is based on the high affinity of the MBD2b/MBD3L1 complex for double-stranded CpG-methylated DNA. MIRA has been used in combination with microarray platforms to map DNA methylation patterns across the human genome.

Download full-text


Available from: Gerd Pfeifer, Nov 19, 2014
  • Source
    • "e l s e v i e r . c o m / g e n o m i c s -d a t a / (MIRA) based on the high affinity of the MBD2b/MBD3L1 protein complex for double-stranded CpG-methylated DNA to pull down only CpG methylated fragments [4]. These fragments were then amplified using the WGA3 kit (Sigma), to produce copies of the DNA sequences. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A precise biological mechanism by which cadmium acts as a developmental toxicant is unknown but is suggested to include an epigenetic basis. In prior work, we analyzed CpG island methylation levels within gene promoters (n=16,421) in leukocytes collected from mothers and their infants from a pregnancy cohort in Durham County, North Carolina. The CpG methylation levels were examined in relationship to prenatal exposure to cadmium and/or cotinine to identify genes and pathways influenced by in utero exposure. In the present article, we provide an enhanced description of the data collection and processing to facilitate cross-study comparisons. Data are available within the Gene Expression Omnibus database (GSE67976).
    Genomics Data 09/2015; 5:378-380. DOI:10.1016/j.gdata.2015.07.001
  • Source
    • "To detect potential genome-wide changes in DNA methylation patterns after the γ radiation treatment, the methylated-CpG island recovery assay (MIRA) combined with microarray analysis was used [34], [35], [36]. Nimblegen’s Signalmap program was used to visualize the DNA methylation data ( "
    [Show abstract] [Hide abstract]
    ABSTRACT: Environmental chemicals and radiation have often been implicated in producing alterations of the epigenome thus potentially contributing to cancer and other diseases. Ionizing radiation, released during accidents at nuclear power plants or after atomic bomb explosions, is a potentially serious health threat for the exposed human population. This type of high-energy radiation causes DNA damage including single- and double-strand breaks and induces chromosomal rearrangements and mutations, but it is not known if ionizing radiation directly induces changes in the epigenome of irradiated cells. We treated normal human fibroblasts and normal human bronchial epithelial cells with different doses of γ-radiation emitted from a cesium 137 ((137)Cs) radiation source. After a seven-day recovery period, we analyzed global DNA methylation patterns in the irradiated and control cells using the methylated-CpG island recovery assay (MIRA) in combination with high-resolution microarrays. Bioinformatics analysis revealed only a small number of potential methylation changes with low fold-difference ratios in the irradiated cells. These minor methylation differences seen on the microarrays could not be verified by COBRA (combined bisulfite restriction analysis) or bisulfite sequencing of selected target loci. Our study shows that acute γ-radiation treatment of two types of human cells had no appreciable direct effect on DNA cytosine methylation patterns in exposed cells.
    PLoS ONE 09/2012; 7(9):e44858. DOI:10.1371/journal.pone.0044858 · 3.23 Impact Factor
  • Source
    • "The MIRA-based microarray analysis was performed as described previously [17] with minor modifications. Briefly, DNA was first separated from four pairs of matched fresh-frozen maternal peripheral blood and placental tissue samples using the standard phenol/chloroform technique. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The noninvasive prenatal diagnosis procedures that are currently used to detect genetic diseases do not achieve desirable levels of sensitivity and specificity. Recently, fetal methylated DNA biomarkers in maternal peripheral blood have been explored for the noninvasive prenatal detection of genetic disorders. However, such efforts have covered only chromosomal aneuploidy, and fetal methylated DNA biomarkers in maternal whole blood for detecting single-gene diseases remain to be discovered. To address this issue, we systematically screened significantly hypermethylated genes in fetal tissues and compared them with maternal peripheral blood potential in an attempt to detect fetal genes in maternal peripheral blood. First, the methylated-CpG island recovery assay combined with a CpG island array was performed for four fetus-toward placental tissues and the corresponding maternal peripheral bloods. Subsequently, direct bisulfite sequencing and combined bisulfite restriction analysis (COBRA) were carried out to validate the methylation status of the hypermethylated genes that were identified by the microarray analysis. Three hundred and ten significantly hypermethylated genes in the placental tissues were detected by microarray. From the top 15 hypermethylated genes detected by microarray, two were selected for sequencing validation in placental tissue and chorionic villus samples and four were selected for COBRA validation in four placental tissues, ten amniotic fluids and five chorionic villus samples. The six selected genes were confirmed to be hypermethylated in placental tissue and chorionic villus samples, but methylation of the genes could not be detected in the amniotic fluids. Of the many hypermethylated genes and methylation sites that were found in the fetal tissues, some have great potential to be developed into molecular markers for noninvasive prenatal diagnosis of monogenic disorders. Further clinical studies are warranted to confirm these findings.
    BMC Medical Genomics 06/2012; 5(1):26. DOI:10.1186/1755-8794-5-26 · 2.87 Impact Factor
Show more